The varied beneficial effects of ivermectin (Mectizan) treatment, as observed within onchocerciasis foci in south-eastern Nigeria

• Published in: Annals of tropical medicine and parasitology 2007-10, Vol.101 (7), p.593-600
• Main Authors: Anosike, J. C., Dozie, I. N. S., Ameh, G. I., Ukaga, C. N., Nwoke, B. E. B., Nzechukwu, C. T., Udujih, O. S., Nwosu, D. C.
• Format: Article
• Language: English
• Subjects: Adult; Amenorrhea - drug therapy; Animals; Antiparasitic Agents - therapeutic use; Appetite - drug effects; Biological and medical sciences; Diseases caused by nematodes; Female; Filariases; General aspects; Helminthic diseases; Humans; Infectious diseases; Ivermectin - therapeutic use; Libido - drug effects; Lice Infestations - drug therapy; Lymphatic filariases; Male; Medical sciences; Musculoskeletal Diseases - drug therapy; Nigeria; Onchocerciasis - drug therapy; Onchocercosis; Pain - drug therapy; Parasitic diseases; Pediculus; Pruritus - drug therapy; Qualitative Research; Scalp Dermatoses - drug therapy; Skin Diseases - drug therapy; Treatment Outcome; Vision Disorders - drug therapy
• ISSN: 0003-4983; 1364-8594
• DOI: 10.1179/136485907X229022

In the treatment of humans, ivermectin (Mectizan ® ), a semi-synthetic macrocyclic lactone, is now primarily used as a rapid microfilaricide. The drug has several other benefits, however, and these have recently been investigated in five states in south-eastern Nigeria, where there have been mass treatments with ivermectin, for the control of Onchocerca volvulus, for more than 10 years. Between the January and December of 2005, 3125 adult onchocerciasis patients (each aged ≥20 years and known to have at least one clinical sign of onchocerciasis) were enlisted, clinically examined and interviewed. Relevant data were collected in the interviews, using a structured, pre-tested questionnaire, and in personal and focus-group discussions. Overall, 612 (19.6%) of the subjects reported that they had had nodules that had disappeared following repeated doses of ivermectin, although only 83.8% of the 612 attributed their nodule clearance to ivermectin (the other 16.2% being unsure of the cause). A larger percentage of the subjects (24.6%) reported that they had expelled intestinal helminths following the last round of ivermectin treatment (i.e. been dewormed). Other side-benefits reported in the study were improved vision (11.7% of subjects), reversal of secondary amenorrhea (4.5%), increased appetite (22.3%), reduction in arthritic or other musculo-skeletal pain (7.9%), reductions in the severity of body itching (18.5%) and skin rash (17.3%), darkening of leopard skin (6.6%), improved libido in men (6.6%), and clearance of head lice (4.5%). If, via health education, the local communities could be made more aware of the side-benefits of ivermectin treatment, the sustainability of the on-going programme of community-directed treatment with ivermectin (CDTI) in south-eastern Nigeria would probably be improved.